Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-DΔNΔC

Experimental Cell Research

Volumn 316, Issue 6, 2010, Pages 907-914

  Papiewska Pajak, Izabela ^a   Boncela, Joanna ^b   Przygodzka, Patrycja ^b   Cierniewski, Czeslaw S ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

Endothelial cells; Integrins; Migration assay; Proteomics; VEGF D

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVBETA5 INTEGRIN; BETA2 INTEGRIN; CD147 ANTIGEN; CD45 ANTIGEN; CD98 ANTIGEN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR; VASCULOTROPIN D; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UMBILICAL VEIN; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE;

EID: 77649182026     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.01.014     Document Type: Article

References (31)

1. Bussolati B., Deambrosis I., Russo S., Deregibus M.C., and Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 17 (2003) 1159-1161
2. Bussolati B., Deregibus M.C., and Camussi G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr. Vasc. Pharmacol. (2010) Jan 1. [Electronic publication ahead of print]
3. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., and Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 548-553
4. McColl B.K., Paavonen K., Karnezis T., Harris N.C., Davydova N., Rothacker J., Nice E.C., Harder K.W., Roufail S., Hibbs M.L., Rogers P.A.W., Alitalo K., Stacker S.A., and Achen M.G. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J. 21 (2007) 1088-1098
5. Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., Nice E., Roufail S., Simpson R.J., Moritz R., Karpanen T., Alitalo K., and Achen M.G. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274 (1999) 32127-32136
6. Marconcini L., Marchio S., Morbidelli L., Cartocci E., Albini A., Ziche M., Bussolino F., and Oliviero S. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9671-9676
7. Byzova T.V., Goldman C.K., Jankau J., Chen J., Cabrera G., Achen M.G., Stacker S.A., Carnevale K.A., Siemionow M., Deitcher S.R., and DiCorleto P.E. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99 (2002) 4434-4442
8. Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.L., Kholova I., Kauppinen R.A., Achen M.G., Stacker S.A., Alitalo K., and Herttuala S.Y. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92 (2003) 1098-1106
9. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., Petrova T.V., Kubo H., Thurston G., McDonald D.M., Achen M.G., Stacker S.A., and Alitalo K. Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20 (2001) 1223-1231
10. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., and Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7 (2001) 186-191
11. Von Marschall Z., Scholz A., Stacker S.A., Achen M.G., Jackson D.G., Alves F., Schirner M., Haberey M., Thierauch K.H., Wiedenmann B., and Rosewicz S. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int. J. Oncol. 27 (2005) 669-679
12. Kopfstein L., Veikkola T., Djonov V.G., Baeriswyl V., Schomber T., Strittmatter K., Stacker S.A., Achen M.G., Alitalo K., and Christofori G. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 170 (2007) 1348-1361
13. Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D., Stacker S.A., Achen M.G., and Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20 (2001) 4762-4773
14. Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., and Zachary I. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J. Biol. Chem. 279 (2004) 36148-36157
15. Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.L., Kholová I., Kauppinen R.A., Achen M.G., Stacker S.A., Alitalo K., and Ylä-Herttuala S. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92 (2003) 1098-1106
16. Bhardwaj S., Roy H., Gruchala M., Viita H., Kholova I., Kokina I., Achen M.G., Stacker S.A., Hedman M., Alitalo K., and Ylä-Herttuala S. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Human Gene Therapy 14 (2003) 1451-1462
17. Rutanen J., Turunen A.M., Teittinen M., Rissanen T.T., Heikura T., Koponen J.K., Gruchala M., Inkala M., Jauhiainen S., Hiltunen M.O., Turunen M.P., Stacker S.A., Achen M.G., and Ylä-Herttuala S. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Therapy 12 (2005) 980-987
18. Rutanen J., Rissanen T.T., Markkanen J.E., Gruchala M., Silvennoinen P., Kivelä A., Hedman A., Hedman M., Heikura T., Ordén M.R., Stacker S.A., Achen M.G., Hartikainen J., and Ylä-Herttuala S. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109 (2004) 1029-1035
19. De S., Razorenova O., McCabe N.P., O'Toole T., Qin J., and Byzova T.V. VEGF-integrin interplay controls tumor growth and vascularization. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 7589-7594
20. Pawlowska Z., Baranska P., Jerczynska H., Koziolkiewicz W., and Cierniewski C.S. Heat shock proteins and other components of cellular machinery for protein synthesis are up-regulated in vascular endothelial cell growth factor-activated human endothelial cells. Proteomics 5 (2005) 1217-1227
21. Wang J.F., Zhang X.F., and Groopman J.E. Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J. Biol. Chem. 276 (2001) 41950-41957
22. Mountain M.J., Singh M., and Singh K. Interleukin-1β-mediated inhibition of the processes of angiogenesis in cardiac microvascular endothelial cells. Life Sciences 82 (2008) 1224-1230
23. Unemori E.N., Ferrara E.N.N., Bauer E.A., and Amento E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol. 153 (1992) 557-562
24. Smolarczyk K., Boncela J., Szymanski J., Gills A., and Cierniewski CS. Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysis. Arterioscler Thromb Vasc Biol 25 (2005) 2679-2684
25. Degryse B., Neels J.G., and Czekay R.P. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J. Biol. Chem. 279 (2004) 22595-22604
26. Al-Nedawi K.N., Czyz M., Bednarek R., Szemraj J., Swiatkowska M., Cierniewska-Cieslak A., Wyczolkowska J., and Cierniewski C.S. Thymosin β4 induces the synthesis of plasminogen activator inhibitor-1 in cultured endothelial cells and increases its extracellular expression. Blood 103 (2004) 1319-1324
27. 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J. Biol. Chem. 276 (2001) 35305-35311
28. Pepper M.S., and Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. 32 (1990) 319-327
29. Loskutoff D.J., Curriden S.A., Hu G., and Deng G. Regulation of cell adhesion by PAI-1. APMIS 107 (1999) 54-61
30. Bougaten F., Quemener C., Kellouche S., Naimi B., Podgorniak M.P., Millot G., Gabison E.F., Calvo F., Dosquet C., Lebbe C., Menashi S., and Mourah S. EMMPRIN promotes angiogenesis through HIF-2α mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 116 (2009) 5547-5556
31. Fenczik C.A., Sethi T., Ramos J.W., Hughes P.E., and Ginsberg M.H. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 390 (1997) 81-85